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full length RLuc8 C-terminal fusions with Gαs-mVenus (red symbols and curves) or Gαi-mVenus (black symbols and curves) together with unlabeled β 1 and γ 2 ; or the unfused receptor (c-d) together with Gαs-RLuc (red symbols and curves) or Gαi-RLuc (black symbols and curves) and mVenus-γ 2 and unfused β 1 were harvested 48 h post-transfection, washed with PBS, centrifuged and resuspended in PBS. Cells were distributed in 96-well plates and preincubated with coelenterazine H for 1 min and then with increasing concentrations of dopamine for 1 min. BRET 1 was performed as described in Materials and Methods and results were fit by non-linear regression to a sigmoidal dose-response relationship against the dopamine concentration. Representative experiments performed with triplicate samples (error bars represent S.E.M.) are shown, and summary data are presented in Supplementary Table 1.
Supplementary Figure 2.
Optimization and characterization of the full length receptor-G protein BRET biosensors. HEK 293T cells transiently expressing D1R (a-b) or D2R (ch) full length RLuc8 C-terminal fusions, in the presence (g-h) or in the absence (c-f) of unfused D1R, together with Gαs-mVenus (red symbols and curves) or Gαi-mVenus (black symbols and curves) and unlabeled β 1 and γ 2 or not (f, open symbols) were prepared and analyzed as described in SF1. Representative experiments performed with triplicate samples (error bars represent S.E.M.) are shown, and summary data are presented in Supplementary Table 1.
Supplementary Figure 3. G protein biosensor detects an active conformation. HEK 293T cells transiently expressing D1R and Gαs-mRLuc (a) or D2R and Gαi-mRLuc (b)
together with mVenus-γ 2 unlabeled β 1 and γ 2 were prepared as explained for SF1. In experiments in which antagonists were used (open symbols and curves), the antagonists (1 µM) were preincubated for 15 mins at RT before the addition of the substrate and the tested agonist. BRET 1 was measured as explained in Material and Methods and analyzed as for SF1. Representative experiments performed with triplicate samples (error bars represent S.E.M.) are shown, and summary data are presented in Supplementary Table 1.
Supplementary Figure 4. Characterization of a new biosensor to detect BRET changes at the level of the receptor and β 1 γ 2 . HEK 293T cells coexpressing D1R (a) or D2R (b)
full length RLuc8 C-terminal fusions together with V2 (C-terminal domain of mVenus, aa 156-end) at the N terminus of the β 1 subunit and V1 (N terminus of mVenus, aa 1-155) at the N terminus of the γ 2 with or without coexpression of the corresponding unlabeled Gα subunit were prepared and analyzed as described in SF1. Representative experiments performed with triplicate samples (error bars represent S.E.M.) are shown, and summary data are presented in Supplementary Table 1.
Supplementary Figure 5. D2R interacts similarly with itself and with D1R and ligand binding to D2R and/or to D1R does not alter luminescence complementation. HEK 293T cells transiently coexpressing D2R-L1 and D2R-L2 (a-open symbols and dashed lineand c) or D1R-L2 (a-closed symbols and continuous line-and b)
were harvested 48 h post-transfection, washed with PBS, centrifuged and resuspended in PBS. Unfiltered luminescence was recorded for 1 s (Gain 3000) in the presence or in the absence of several selective and nonselective agonists and selective inverse agonists. Background was determined with cells expressing only one of the receptor probes and the signal to background ratio was plotted against the FACS ratio (a). For the FACS ratio, cells transfected in parallel were labeled with primary and secondary antibodies as described in the Material and Methods. Relative staining for each receptor was determined independently in the same cells with the same secondary anti-mouse antibody to determine the FACS ratio. Representative results from at least 2-3 independent experiments are shown. Figure 6 . D1R agonism at D1R homo-and heteromers. HEK 293T cells coexpressing D1R-L1, D1R-L2 (a-d); or D2R-L1, D1R-L2 together with Gαs-mVenus (eh) and with unlabeled βγ were prepared as explained for SF1. In experiments in which antagonists were used (c-d,g-h, open symbols and curves), the antagonists (1 µM) were preincubated for 15 mins at RT before the addition of the substrate and the tested agonist. BRET 1 was measured as explained in Material and Methods and analyzed as for SF1. The graphs are representative of 1-5 independent experiments performed with triplicate samples (error bars represent S.E.M.), and summary data are presented in Supplementary Table 1.
Supplementary

Supplementary Figure 7.
Characterization of the Gα-based biosensors for D2R homomers. HEK 293T cells coexpressing D2R-L1, D2R-L2 and Gαs-mVenus (red in cd) or Gαi-mVenus (black in b-d) together with unlabeled βγ were prepared as described in SF1. In experiments in which antagonists were used (c-f, open symbols), the antagonists (1 µM) were preincubated for 15 mins at RT before the addition of the substrate and the tested agonist. BRET 1 was measured as explained in Material and Methods and analyzed as for SF1. Representative experiments performed with triplicate samples (error bars represent S.E.M.) are shown, and summary data are presented in Supplementary Table 1 . Supplementary Figure 8 . Characterization of the β 1 γ 2 and γ 2 -based biosensors for D2R homomers. HEK 293T cells coexpressing D2R split RLuc8 C-terminal fusions together with mVenus-γ 2 (a) or V2 (C-terminal domain of mVenus, aa 156-end) at the N terminus of the β 1 subunit and V1 (N terminus of mVenus, aa 1-155) at the N terminus of the γ 2 and unlabeled Gαi (b-f) together with unlabeled Gαi or not (c, open squares) and unlabeled β 1 and were prepared as described in SF1. In experiments in which antagonists were used (e-f, open symbols), the antagonists (1 µM) were preincubated for 15 mins at RT before the addition of the substrate and the tested agonist. BRET 1 was measured as explained in Material and Methods and analyzed SF1. Representative experiments performed with triplicate samples (error bars represent S.E.M.) are shown, and summary data are presented in Supplementary Table 1.
Supplementary Figure 9. Similar BRET after swapping the protomers in the D1R-D2R
heteromer. HEK 293T cells coexpressing D1R-L1, D2R-L2 and Gαs-mVenus (a) or Gαi-mVenus (b) together with unlabeled βγ were prepared as described in SF1. BRET 1 was measured as explained in Material and Methods and analyzed as for SF1. Representative experiments performed with triplicate samples (error bars represent S.E.M.) are shown, and summary data are presented in Supplementary Table 1.
Supplementary Figure 10. D1R agonists target D1R and D2R agonists target D2R to
cause the G protein conformational changes: a mutagenesis approach. HEK 293T cells coexpressing wild-type or mutant (D114A)D2R-L1, D1R-L2 and Gαs-mVenus (a) or Gαi-mVenus (b) together with unlabeled βγ were prepared as described SF1. BRET 1 was measured as explained in Material and Methods and analyzed as for SF1. Representative experiments performed with triplicate samples (error bars represent S.E.M.) are shown, and summary data are presented in Supplementary Table 1. 
